Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?

Clinical Colorectal Cancer

Volumn 7, Issue 3, 2008, Pages 206-211

  Douillard, Jean Yves ^a   Bennouna, Jaafar ^a   Senellart, Helene ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Bevacizumab; Capecitabine; Fluoropyrimidines; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HAZARD RATIO; HEALTH CARE SYSTEM; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; INCIDENCE; METASTASIS; NEUROTOXICITY; OVERALL SURVIVAL; PRESCRIPTION; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; STOMATITIS; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 44449153117     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.029     Document Type: Note

References (24)

1. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. Meta-Analysis Group in Cancer. J Clin Oncol 2004; 18:3766-75.
2. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16:3537-41.
3. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-47.
4. Douillard JY, Cunningham D, Roth A, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000; 355:1041-7.
5. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
7. Van Cutsem E, Bodoky G, Kyung Roh J, et al. CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC). Eur J Cancer 2007; 5:235 (Abstract 3001).
8. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-106.
9. Van Hoff P, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-92.
10. Welles L, Hochster H, Ramanathan R, et al. Preliminary results of a randomized study of the safety and tolerability of three oxaliplatin-based regimens as first-line treatment for advanced colorectal cancer (CRC) ("TREE" study). Proc Am Soc Clin Oncol 2004; 23:254 (Abstract 3537).
11. Cassidy J, Clarke S, Diaz-Rubio E. First efficacy and safety results from XELOX-1/NO16966, a randomized 2x2 factorial phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Presented at: 2006 Annual Meeting of the European Society of Medical Oncology; September 29-October 3, 2006; Istanbul, Turkey. Abstract LBA 3.
12. Ducreux M, Bennouna J, Hebbar M, et al. Efficacy and safety findings from a randomized phase III study of capecitabine+oxaliplatin vs. infusional 5-FU/acid folinic+oxaliplatin (FOLFOX6) as first-line treatment for metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25(18 suppl):170s (Abstract 4029).
13. Diaz-Rubio E, Tabernero J, Gomez-Espana A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumor trial. J Clin Oncol 2007; 25:4224-30.
14. Porschen R, Arkenau H, Kubicka S, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO colorectal study group. J Clin Oncol 2007; 25:4217-23.
15. Cornelia P, Massidda B, Filippelli G, et al. Capecitabine or Fluorouracil/Folinic Acid IV Bolus plus Eloxatin Evaluation (COFFEE trial) in metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Group (SICOG) phase III trial 0401. Eur J Cancer 2007; 5:248 (Abstract 3044).
16. Hochster H, Hart L, Ramanathan R, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final results of the TREE-study. J Clin Oncol 2006; 24: 24(18 suppl):148s (Abstract 3510).
17. Berry S, Cunningham D, Michael M, et al. Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and fluoropyrimidines for mCRC: first BEAT trial. Eur J Cancer 2007; 5:241 (Abstract 3020).
18. Arkenau H, Arnold D, Diaz-Rubio E, et al. Capecitabine and oxaliplatin as first-line treatment in patients with metastatic colorectal cancer (MCRC): a combined analysis of randomized phase II-III trials. Presented at: 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 342.
19. Twelves C, Gollins S, Grieve R, et al. A randomized cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006; 17:239-45.
20. Hebbar M, Bennouna J, Boige V, et al. Safety and quality of life (QoL) findings from a randomized phase III study of capecitabine+oxaliplatin (XELOX) vs. infusional 5-FU/folinic acid (FA)+oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25(18 suppl):188s (Abstract 4099).
21. Perrocheau G, Bennouna J, Ducreux, et al. Cost-minimization analysis of a phase III study of capecitabine+oxaliplatin vs. infusional 5-FU/folinic acid (FA)+oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting. J Clin Oncol 2007; 25(18 suppl):184s (Abstract 4083).
22. Mayer RJ. Should Capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 2007; 27:4164-7.
23. Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006; 94:1122-9.
24. Chu E, Cartwright TH. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer. J Clin Oncol 2008; 26:2224-26. Author reply 2228.